What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?
The share price of JAGSNPHARM as on 29th April 2025 is ₹227.46. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are- Past 1 week: 7.11%
- Past 1 month: 7.90%
- Past 3 months: 4.61%
- Past 6 months: 23.91%
- Past 1 year: 65.36%
- Past 3 years: 86.13%
- Past 5 years: 1970.28%
What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 0.86.What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1545.10 Cr as of 29th April 2025.What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?
The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹328.04 and the 52-week low is ₹110.What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?
The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 68.79. The P/B (price-to-book) ratio is 8.24.Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?
You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jagsonpal Pharmaceuticals Ltd
JAGSNPHARM Share Price
227.462.25% (-5.24)
JAGSNPHARM Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
JAGSNPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.53 | 8.24 | 0.86% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.16 | 6.42 | 0.53% |
JAGSNPHARM Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
JAGSNPHARM Company Profile
Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.
JAGSNPHARM Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
46.14
1Y Return
21.03%
Buy Reco %
88.24
CIPLA
PE Ratio
30.47
1Y Return
10.45%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
68.14
1Y Return
24.10%
Buy Reco %
68.00
MANKIND
PE Ratio
55.22
1Y Return
7.72%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.88
1Y Return
4.82%
Buy Reco %
46.67
JAGSNPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JAGSNPHARM Stock Summary · January 2025
Jagsonpal Pharmaceuticals Limited has demonstrated robust financial performance, achieving a remarkable 57% year-on-year revenue growth in Q3 FY25, bolstered by strategic initiatives and operational efficiencies. Despite facing challenges in certain product lines due to intense market competition and counterfeit issues, the company is optimistic about future growth, targeting a 12% to 14% increase in top-line revenue. The integration of recent acquisitions is progressing well, contributing positively to profitability, while a focus on enhancing sales force productivity remains critical. With a strong emphasis on cash utilization for strategic growth and potential acquisitions, the company is committed to maintaining its leadership in the gynae segment, which constitutes half of its revenues.
Key Points on Jagsnpharm Stock
JAGSNPHARM Stock Growth Drivers
5Strong Financial Performance
Jagsonpal Pharmaceuticals Limited reported significant financial achievements for Q3 FY25, including revenues of approximately INR
Strategic Corporate Developments
The company completed a strategic divestment of its Faridabad facility for INR 41 crores, contributing
JAGSNPHARM Stock Challenges
4Performance Challenges of Divatrone
Divatrone is facing significant performance challenges in a hyper-competitive market, leading to a notable drop
Concerns Over ESOP Costs
The company is experiencing fluctuations in ESOP costs, with the current quarter's expense reported at
JAGSNPHARM Forecasts
Price
Revenue
Earnings
JAGSNPHARM Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeJAGSNPHARM Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeJAGSNPHARM Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeJAGSNPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
JAGSNPHARM Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 144.15 | 157.14 | 126.99 | 168.26 | 161.10 | 192.34 | 221.01 | 242.44 | 217.98 | 284.73 | ||||||||||
Raw Materials | 65.35 | 67.34 | 65.19 | 53.43 | 54.94 | 75.50 | 83.35 | 88.04 | 76.08 | 211.91 | ||||||||||
| Power & Fuel Cost | 2.26 | 2.12 | 1.00 | 1.41 | 0.64 | 0.52 | 0.47 | 0.29 | 0.17 | |||||||||||
| Employee Cost | 37.84 | 40.95 | 41.88 | 46.61 | 50.37 | 53.98 | 57.68 | 65.18 | 61.80 | |||||||||||
| Selling & Administrative Expenses | 26.58 | 30.19 | 27.56 | 32.23 | 38.34 | 31.88 | 42.50 | 41.66 | 41.09 | |||||||||||
| Operating & Other expenses | -0.34 | -2.50 | 2.01 | 23.81 | 5.75 | 6.99 | 8.56 | 10.85 | 6.50 | |||||||||||
EBITDA | 12.46 | 19.04 | -10.65 | 10.77 | 11.06 | 23.47 | 28.45 | 36.42 | 32.34 | 72.82 | ||||||||||
| Depreciation/Amortization | 3.09 | 1.99 | 0.32 | 1.02 | 1.13 | 1.09 | 1.53 | 1.21 | 1.66 | 6.22 | ||||||||||
| PBIT | 9.37 | 17.05 | -10.97 | 9.75 | 9.93 | 22.38 | 26.92 | 35.21 | 30.68 | 66.60 | ||||||||||
| Interest & Other Items | 5.30 | 2.64 | 0.66 | 0.75 | 0.51 | 0.51 | 0.29 | 0.41 | 0.81 | 0.93 | ||||||||||
| PBT | 4.07 | 14.41 | -11.63 | 9.00 | 9.42 | 21.87 | 26.63 | 34.80 | 29.87 | 65.67 | ||||||||||
| Taxes & Other Items | 0.83 | 2.53 | -0.08 | 1.78 | 1.54 | 4.82 | 7.78 | 8.09 | 7.41 | 13.35 | ||||||||||
| Net Income | 3.24 | 11.88 | -11.55 | 7.22 | 7.88 | 17.05 | 18.85 | 26.71 | 22.46 | 52.32 | ||||||||||
| EPS | 0.49 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.41 | 7.92 | ||||||||||
| DPS | 0.04 | 0.04 | 0.04 | 0.10 | 0.20 | 0.40 | 1.60 | 2.00 | 2.00 | 2.00 | ||||||||||
| Payout ratio | 0.08 | 0.02 | — | 0.09 | 0.17 | 0.15 | 0.56 | 0.49 | 0.59 | 0.25 |
JAGSNPHARM Company Updates
FY 2014
Annual report
PDFFY 2015
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFJAGSNPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 68.79 | 8.24 | 0.86% |
| Sun Pharmaceutical Industries Ltd | 46.14 | 6.58 | 0.73% |
| Cipla Ltd | 30.47 | 4.69 | 0.84% |
| Torrent Pharmaceuticals Ltd | 68.14 | 16.46 | 0.84% |
JAGSNPHARM Stock Price Comparison
Compare JAGSNPHARM with any stock or ETFCompare JAGSNPHARM with any stock or ETF
JAGSNPHARM
JAGSNPHARM Shareholdings
JAGSNPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JAGSNPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JAGSNPHARM Shareholding Pattern
JAGSNPHARM Shareholding History
Foreign Institutions
smallcases containing JAGSNPHARM stock
Looks like this stock is not in any smallcase yet.
JAGSNPHARM Events
JAGSNPHARM Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JAGSNPHARM has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.56 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JAGSNPHARM Upcoming Dividends
No upcoming dividends are available
JAGSNPHARM Past Dividends
Cash Dividend
Ex DateEx DateSep 6, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateAug 21, 2023
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 21, 2023
Cash Dividend
Ex DateEx DateOct 29, 2021
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Oct 29, 2021
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2020
JAGSNPHARM Stock News & Opinions
Articles & Videos
Corporate
Jagsonpal Pharmaceuticals allots 39,850 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 39,850 equity shares under ESOP. With this allotment, the paid up equity share capital has increased to Rs. 13,28,76,960 (constituting of 6,64,38,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 11,575 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 11,575 equity shares under ESOP. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,74,110 (constituting of 6,63,87,055 equity shares of Rs. 2/- each) to Rs. 13,27,97,260 (constituting of 6,63,98,630 equity shares of Rs. 2/- each). Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 22,150 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 22,150 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employee of the Company, upon exercise of vested options. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,29,810 (constituting of 6,63,64,905 equity shares of Rs. 2/- each) to Rs. 13,27,74,112 (constituting of 6,63,87,056 equity shares of Rs. 2/- each).Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Jagsonpal Pharma gains after reporting strong Q3 numbers
Revenue from operations surged 56.7% to Rs 74.03 crore recorded in the quarter ended 31 December 2024. Profit before exceptional items and tax stood at Rs 15.48 in Q3 FY24, steeply higher than Rs 5.27 crore posted in Q3 FY23. The company reported an exceptional item of Rs 23.18 crore during the quarter. The company's operating EBITDA surged by 185% to Rs 171 crore in Q3 FY25, compared to Rs 60 crore recorded in the same quarter last year. The EBITDA margin also improved to 23.1% in Q3 FY25, up from 12.8% in Q3 FY24. On nine-month basis, the company's net profit climbed 158% to Rs 48.78 crore on 27.2% increase in revenue to Rs 210.16 crore in 9M FY25 over 9M FY24. The company reported a strong balance sheet, having concluded the sale of its Faridabad facility for Rs 41 crore, resulting in exceptional income during Q3 FY25. As of 31 December 2024, the company maintains a robust cash balance of Rs 132.1 crore. Regarding its successful acquisition integration, the company stated that the integration of the acquired business is progressing well. Q3 FY25 marks the second full quarter of operations, with performance aligning with expectations. Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 707.83% in the December 2024 quarter
Net profit of Jagsonpal Pharmaceuticals rose 707.83% to Rs 31.99 crore in the quarter ended December 2024 as against Rs 3.96 crore during the previous quarter ended December 2023. Sales rose 56.74% to Rs 74.03 crore in the quarter ended December 2024 as against Rs 47.23 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales74.0347.23 57 OPM %21.387.18 - PBDT17.905.68 215 PBT15.495.27 194 NP31.993.96 708 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to declare Quarterly Result
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals fixes record date for stock split
Jagsonpal Pharmaceuticals has fixed 08 January 2025 as record date for stock split of the Company such that 1 (one) equity share having face value of Rs. 5/- (Rupees five only) each, fully paid-up, be sub-divided into such number of equity shares having face value of Rs. 2 (Rupee two only) each, fully paid up. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 31,040 equity shares under ESOP
Jagsonpal Pharmaceuticals has allotted 31,040 equity shares under ESOP. Consequently, the paid up equity share capital has increased to Rs. 13,27,29,810 (constituting of 2,65,45,962 equity shares of Rs. 5/- each). Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 53.41% in the September 2024 quarter
Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended September 2024 as against Rs 7.47 crore during the previous quarter ended September 2023. Sales rose 29.15% to Rs 74.69 crore in the quarter ended September 2024 as against Rs 57.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales74.6957.83 29 OPM %21.8114.47 - PBDT17.7110.42 70 PBT15.379.96 54 NP11.467.47 53 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to table results
Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.31%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 0.08% to 0.06%
Over the last 5 years, net income has grown at a yearly rate of 25.48%, vs industry avg of 15.28%